Pricing Log in Create free account

Keros Therapeutics, Inc. (KROS) vs SAB Biotherapeutics, Inc. (SABS)

Keros Therapeutics, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and SAB Biotherapeutics, Inc. are of similar size ($235.7M and $220.1M). SAB Biotherapeutics, Inc. grew revenue faster over the last twelve months: −60.3% against −84.6%. Across the 14 metrics below, Keros Therapeutics, Inc. leads on 11 and SAB Biotherapeutics, Inc. on 3.

Valuation

Metric KROS SABS Biotechnology median
P/E n/m n/m 8.42
P/S 6.62 126.93 10.01
P/B 0.84 0.96 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA 0.38 n/m 0.61
EV/Sales (1.14) 65.73 9.41
Earnings yield (33.33%) (24.71%) (31.85%)
Free cash flow yield (22.06%) (27.81%) (24.58%)

Profitability

Metric KROS SABS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (17.16%) (19.21%) (56.36%)
Return on assets (15.92%) (16.24%) (48.04%)
Return on invested capital (1,345.30%) (38.97%) 0.00%

Growth

Metric KROS SABS Biotechnology median
Revenue growth (TTM) (84.55%) (60.26%) 6.02%
EPS growth (last fiscal year) 146.00% 78.53% 30.26%
Revenue growth, 5-year CAGR 89.45% — 9.41%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric KROS SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 21.96 9.22 4.72
Net debt to EBITDA (4.16) 2.03 0.96

Dividend

Metric KROS SABS Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric KROS SABS Biotechnology median
Market cap 220.08m 235.66m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack